HBIO Wins Legal Judgment for Use of Harvard Apparatus Name

HOLLISTON, Mass., May 15, 2002 (BW HealthWire) -- Harvard Bioscience, Inc., (Nasdaq: HBIO) today announced that the US District Court (District of Massachusetts) had ruled in favor of HBIO's request for summary judgement for its use of the Harvard Apparatus name. Summary judgment was requested by HBIO in response to the lawsuit brought against it by Harvard University for alleged trademark infringement.

In granting the partial summary judgement Judge Richard Stearns wrote the following: "Harvard University's one hundred year delay in interposing an objection to the use of the name Harvard Apparatus by a company that it virtually fathered is beyond the rim of anything a court considering a laches defense has found to be even remotely reasonable."

David Green, President of Harvard Bioscience, said "We completely respect the University's desire to rein in pretenders to its name such as the now infamous www.notHarvard.com (which sold training programs), but Harvard Bioscience is simply not in this category. We have built our own reputation for quality and innovation for over 100 years under the Harvard Apparatus name and for over twenty years under the Harvard Bioscience name. We do not sell educational services and Harvard University does not sell scientific instruments. This judgment is only the first step in the legal process and applies only to the Harvard Apparatus name. We believe we have strong rights to the name Harvard Bioscience and as the second step we will continue to defend vigorously our rights in this name."

About Harvard Bioscience, Inc.

Harvard Bioscience is a global developer, manufacturer and marketer of innovative, enabling tools in drug discovery research at pharmaceutical and biotechnology companies, universities and government laboratories. HBIO sells approximately 10,000 products to thousands of researchers in over 60 countries though its direct sales force, 1,000 page catalog, and through its distributors, the most notable of which is Amersham Biosciences. HBIO has sales and manufacturing operations in the United States, the United Kingdom, Germany, Austria and Belgium with sales facilities in France and Canada. For more information please visit www.harvardbioscience.com

The statements made in this press release that are not statements of historical fact are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to statements about the impact of acquisitions on future revenues, the Company's or managements opinion of analysts' earnings estimates, the possible effect of our technology on the drug development process, the Company's intention to strengthen its market position, the Company's or management's confidence or expectations, the Company's business strategy, the positioning of the Company for growth, the market demand and opportunity for the Company's products, and the Company's plans, objectives and intentions contained in this press release that are not historical facts. Other factors that may cause the Company's actual results to differ materially from those in the forward looking statements include the Company's failure to successfully integrate an acquired business or technology, expand its product offering, to introduce new products or to commercialize new technologies or decreased demand for the Company's products due to changes in our customers needs, financial position, general economic outlook, or otherwise, as well as those set forth under the heading "Important Factors That May Affect Future Operating Results" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2000, as well as other risks described in the Company's public filings or factors, if any, of which the Company is not currently aware. The Company may not update these forward-looking statements, even though its situation may change in the future, unless it has obligations under the Federal securities laws to update and disclose material developments related to previously disclosed information.

CONTACT:
Harvard Bioscience
David Green
508 893 8999
dgreen@harvardbioscience.com

Copyright © 2002 Business Wire. All rights reserved.

Disclaimer:
The information contained within this and other Harvard Bioscience Web pages should be deemed accurate and current as of the date of the most recent update, or if no update information has been provided, the date of issuance. Harvard Bioscience assumes no responsibility for any misincurrances or misstatements which occur as the result of the reading of dated material. Users are strongly encouraged to check dates of issuance and most recent update of any information contained within, or linked to, Harvard Bioscience's web site. For Harvard Bioscience's most current information please reference Harvard Bioscience public filings with the Securities and Exchange Commission located at http://www.sec.gov.